Infection Prevention 2025
Traditional textile curtains contribute to significant environmental waste. Disposable curtains alone generate 140-360kg of textile waste per bed annually, and laundering reusable curtains consumes thousands of litres of water and energy . Silentia screens, in contrast, are built to last, drastically cutting down on hospital waste and resource consumption while aligning with NHS Net Zero goals . Visit Stand 8.
European gloves: safer, cleaner, greener Healthcare-associated infections remain one of the greatest threats to modern healthcare systems. According to the WHO, over 70% of HCAIs are preventable through basic measures such as proper hand hygiene and glove use. ARKA Medical, a company dedicated to advancing infection prevention, introduces two innovative glove lines –
R.Advance and
R.Green – developed in collaboration with European IPC experts and fully aligned with WHO technical guidelines. Arka’s high-quality gloves feature single-glove extraction by the cuff and sanitisable packaging to minimise cross-contamination. They are the only gloves in the world to undergo 100% inspection in a fully automated facility. Compared to traditional gloves, they deliver significantly fewer defects, 81% lower bioburden, and up to 50% greater tensile strength (9N). These features not only enhance clinical safety but also reduce environmental impact, enabling up to 45% savings in glove consumption and waste. Made in Europe,
R.Advance and
R.Green also reinforce supply chain resilience across European healthcare systems. Join ARKA on Stand 15 and discover how these glove lines are setting new standards in performance, safety, and sustainability.
Innovative dressing reduces SSI rates Surgical Site Infections (SSI) are the third most reported type of healthcare-acquired infection and the most costly (Wounds UK, 2020). They place a significant impact on patient welfare as
well as presenting a heavy financial burden for the NHS. The typical average cost is estimated to cost just over £10,000 per person, with deep- incisional SSIs costing a staggering £100,000 per patient (GIRFT, 2019). Reducing SSI rates can reduce readmissions, antibiotic use, offer cost savings and benefit patient quality of life. Essity’s Leukomed Sorbact harnesses a unique, bacteria-binding technology. The physical mode of action has an antimicrobial effect without the release of active substances, making it a safe and effective option for post-op wound care while also supporting Antimicrobial Stewardship (AMS) strategies. A recent independent systematic review of
Leukomed Sorbact concluded that the dressing almost halves SSI rates within 30 days with a confidence interval of over 95% (Rippon et al, 2025). Visit: Stand 35b.
August 2025 I
www.clinicalservicesjournal.com 45
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
